1. Home
  2. BLRX vs SANW Comparison

BLRX vs SANW Comparison

Compare BLRX & SANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • SANW
  • Stock Information
  • Founded
  • BLRX 2003
  • SANW 1980
  • Country
  • BLRX Israel
  • SANW United States
  • Employees
  • BLRX N/A
  • SANW N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • SANW Farming/Seeds/Milling
  • Sector
  • BLRX Health Care
  • SANW Consumer Staples
  • Exchange
  • BLRX Nasdaq
  • SANW Nasdaq
  • Market Cap
  • BLRX 17.3M
  • SANW 16.1M
  • IPO Year
  • BLRX 2011
  • SANW 2010
  • Fundamental
  • Price
  • BLRX $0.10
  • SANW $9.10
  • Analyst Decision
  • BLRX Strong Buy
  • SANW Strong Buy
  • Analyst Count
  • BLRX 2
  • SANW 1
  • Target Price
  • BLRX $5.50
  • SANW $35.00
  • AVG Volume (30 Days)
  • BLRX 18.8M
  • SANW 23.2K
  • Earning Date
  • BLRX 11-25-2024
  • SANW 02-12-2025
  • Dividend Yield
  • BLRX N/A
  • SANW N/A
  • EPS Growth
  • BLRX N/A
  • SANW N/A
  • EPS
  • BLRX N/A
  • SANW N/A
  • Revenue
  • BLRX $21,991,000.00
  • SANW $57,993,775.00
  • Revenue This Year
  • BLRX N/A
  • SANW N/A
  • Revenue Next Year
  • BLRX N/A
  • SANW $9.92
  • P/E Ratio
  • BLRX N/A
  • SANW N/A
  • Revenue Growth
  • BLRX N/A
  • SANW N/A
  • 52 Week Low
  • BLRX $0.08
  • SANW $2.10
  • 52 Week High
  • BLRX $1.44
  • SANW $14.25
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 28.83
  • SANW 63.41
  • Support Level
  • BLRX $0.23
  • SANW $6.93
  • Resistance Level
  • BLRX $0.14
  • SANW $9.99
  • Average True Range (ATR)
  • BLRX 0.03
  • SANW 1.15
  • MACD
  • BLRX -0.00
  • SANW 0.08
  • Stochastic Oscillator
  • BLRX 6.93
  • SANW 70.68

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About SANW S&W Seed Company (NV)

S&W Seed Co is a multi-crop, middle-market agricultural company. It is engaged in the breeding, production, and sale of alfalfa seed and sorghum seed. It also has a growing commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers globally. Its geographical segments include the United States, Australia, Saudi Arabia, Mexico, South Africa, and other countries. Maximum of revenue is earned from USA following Australia second and Mexico third.

Share on Social Networks: